Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Update Following General Election

16 Dec 2019 07:00

RNS Number : 9512W
Sensyne Health PLC
16 December 2019
 

 

 

 

Update Following General Election

 

 

Oxford, UK; 16 December 2019: Sensyne Health plc (LSE: SENS), the British clinical AI technology company, provides an update following the UK General Election which took place on 12 December 2019.

 

The outcome of the UK General Election, returning a Conservative government with a significantly increased majority, has now removed a degree of uncertainty from the operating environment for the Company.

 

Over the past year, the UK government has been moving towards a strategy for the commercial use of anonymised patient data based upon the creation of a sovereign capability at a national level. As announced by the Company on 5 December 2018, Sensyne Health has welcomed this and has formed a portfolio of collaborations with major strategic partners over the past year to enable it to respond positively to these developments.

 

The new government has signalled that NHS investment and reform will be its top priority and it will now be able to progress with the creation of a national patient data capability.

 

The Company and its partners are strategically well positioned, with Sensyne's unique NHS partnership model providing a shared financial return back into the NHS.

 

Lord (Paul) Drayson, CEO of Sensyne Health plc, said: "Sensyne looks forward to working with its NHS partners in 2020 to deliver on this exciting future vision for our National Health Service."

 

 

 

-ENDS-

 

 

For more information please contact:

 

Sensyne Health (www.sensynehealth.com/)

+44 (0) 330 058 1845

Lord (Paul) Drayson, Chief Executive Officer

 

Lorimer Headley, Chief Financial Officer

 

 

 

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott

 

Sukaina Virji

 

Melissa Gardiner

 

sensynehealth@consilium-comms.com

 

 

 

 

About Sensyne Health

Sensyne Health plc is a clinical AI company that works in partnership with the NHS to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is an early signatory to the U.K Department of Health and Social Care's 'Initial Code of Conduct for data-driven health and care technology. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L). For more information, please visit: www.sensynehealth.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAUNSNRKRAUARA

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.